Sandoz: launches paclitaxel generic in US

(CercleFinance.com) - Sandoz has announced the launch of a generic formulation of paclitaxel in the US, the first generic of its reference drug to be approved by the FDA.


Sandoz's protein-bound paclitaxel particles for injectable suspension (albumin-bound) are indicated for the treatment of patients with metastatic breast cancer.

The launch of lyophilised powder for injection containing 100 mg paclitaxel in a single-dose vial for intravenous use follows FDA approval on 8 October 2024.

Sandoz said that an estimated 168,000 women in the US are living with metastatic breast cancer. Although rare, men can also develop metastatic breast cancer. This milestone is further proof of our commitment to providing access to life-changing medicines for all those who need them.


Copyright (c) 2024 CercleFinance.com. All rights reserved.